Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide

Molecular Genetics and Metabolism

Volumn 109, Issue 1, 2013, Pages 93-99

  De Francesco, Pablo N ^a   Mucci, Juan M ^a   Ceci, Romina ^a   Fossati, Carlos A ^a   Rozenfeld, Paula A ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Dendritic cell; Fabry disease; Globotriaosylceramide; Macrophage; Proinflammatory cytokine; TLR4

Indexed keywords

AGALSIDASE ALFA; CYTOKINE; GAMMA INTERFERON; GLOBOTRIAOSYLCERAMIDE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; CHILD; CHILD, PRESCHOOL; CYTOKINES; DENDRITIC CELLS; FABRY DISEASE; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 4; TRIHEXOSYLCERAMIDES;

EID: 84876094499     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.02.003     Document Type: Article

References (31)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 1967, 276:1163-1167.
2. Kint J.A. Fabry's disease: alpha-galactosidase deficiency. Science 1970, 167:1268-1269.
3. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2000, 3733-3774. McGraw-Hill Professional, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
4. Ballabio A., Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 2009, 1793:684-696.
5. Castaneda J.A., Lim M.J., Cooper J.D., Pearce D.A. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 2008, 115:159-174.
6. Barak V., Acker M., Nisman B., Kalickman I., Abrahamov A., Zimran A., et al. Cytokines in Gaucher's disease. Eur. Cytokine Netw. 1999, 10:205-210.
7. Formichi P., Radi E., Battisti C., Pasqui A., Pompella G., Lazzerini P.E., et al. Psychosine-induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients. J. Cell. Physiol. 2007, 212:737-743.
8. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008, 172:112-122.
9. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutière B., Altarescu G., et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neurol. 2000, 47:229-233.
10. Shen J.-S., Meng X.-L., Moore D.F., Quirk J.M., Shayman J.A., Schiffmann R., et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 2008, 95:163-168.
11. Shu L., Park J.L., Byun J., Pennathur S., Kollmeyer J., Shayman J.A. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J. Am. Soc. Nephrol. 2009, 20:1975-1985.
12. Biancini G.B., Vanzin C.S., Rodrigues D.B., Deon M., Ribas G.S., Barschak A.G., et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 2012, 1822:226-232.
13. Rozenfeld P., Agriello E., De Francesco N., Martinez P., Fossati C. Leukocyte perturbation associated with Fabry disease. J. Inherit. Metab. Dis. 2009, 32(Suppl 1):67-77.
14. De Francesco P.N., Mucci J.M., Ceci R., Fossati C.A., Rozenfeld P.A. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells. Effect of globotriaosylceramide. Mol. Genet. Metab. 2011, 104:319-324.
15. Marshall O.J. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics 2004, 20:2471-2472.
16. Helgason C.D., Miller C.L. Basic Cell Culture Protocols 2005, Humana Press, Totowa, N.J.
17. Shoenfeld Y., Gallant L.A., Shaklai M., Livni E., Djaldetti M., Pinkhas J. Gaucher's disease: a disease with chronic stimulation of the immune system. Arch. Pathol. Lab. Med. 1982, 106:388-391.
18. Askari H., Kaneski C.R., Semino-Mora C., Desai P., Ang A., Kleiner D.E., et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 2007, 451:823-834.
19. Namdar M., Gebhard C., Studiger R., Shi Y., Mocharla P., Schmied C., et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS One 2012, 7:e36373.
20. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2812-2817.
21. Kalliokoski R.J., Kalliokoski K.K., Penttinen M., Kantola I., Leino A., Viikari J.S., et al. Structural and functional changes in peripheral vasculature of Fabry patients. J. Inherit. Metab. Dis. 2006, 29:660-666.
22. Sanchez-Niño M.D., Sanz A.B., Carrasco S., Saleem M.A., Mathieson P.W., Valdivielso J.M., et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant. 2011, 26:1797-1802.
23. Galon J., Aksentijevich I., McDermott M.F., O'Shea J.J., Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 2000, 12:479-486.
24. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu. Rev. Immunol. 2009, 27:621-668.
25. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
26. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
27. Rombach S.M., Twickler T.B., Aerts J.M.F.G., Linthorst G.E., Wijburg F.A., Hollak C.E.M. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol. Genet. Metab. 2010, 99:99-108.
28. Weidemann F., Breunig F., Beer M., Sandstede J., Störk S., Voelker W., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur. Heart J. 2005, 26:1221-1227.
29. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:222-227.
30. Jou I., Lee J.H., Park S.Y., Yoon H.J., Joe E.-H., Park E.J. Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am. J. Pathol. 2006, 168:1619-1630.
31. Suzuki M., Sugimoto Y., Ohsaki Y., Ueno M., Kato S., Kitamura Y., et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann-Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J. Neurosci. 2007, 27:1879-1891.